Form 4: Shattuck Labs Director Carrie Brownstein Granted 33,150 Stock Options

Shattuck Labs, Inc. Director Carrie Brownstein was granted 33,150 stock options with an exercise price of $0.82 per share, vesting over one year or prior to the next annual meeting.

Summary

• Carrie Brownstein, a Director of Shattuck Labs, Inc. (STTK), was granted 33,150 stock options.
• The stock options have an exercise price of $0.82 per share.
• The grant date for these options was July 14, 2025.
• The options will vest in full on the earlier of the one-year anniversary of the grant date (July 14, 2026) or immediately prior to the Issuer's next annual meeting of stockholders.
• Vesting is contingent upon Ms. Brownstein's continued service to Shattuck Labs, Inc.
• The options have an expiration date of July 14, 2035.
• Following this transaction, Ms. Brownstein directly beneficially owns 33,150 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates continued alignment of a director's interests with the company's long-term performance through an equity grant, which is a standard practice.

Positives

• The grant of stock options to Director Carrie Brownstein aligns her interests with those of shareholders, incentivizing long-term performance.
• The options have a long expiration date (July 14, 2035), providing ample time for potential value realization.

Negatives

• The stock options do not provide immediate cash benefit to the director.
• The value of the options is dependent on the future performance of Shattuck Labs, Inc.'s common stock exceeding the exercise price of $0.82.

Future Outlook

The stock options granted to Director Carrie Brownstein are set to vest in full on the earlier of July 14, 2026, or immediately prior to the Issuer's next annual meeting of stockholders, contingent on her continued service to Shattuck Labs, Inc. The options have a long-term expiration date of July 14, 2035, indicating a long-term incentive structure.

Industry Context

This Form 4 filing represents a routine equity compensation event for a director in a publicly traded biotechnology company, a common practice to align management and board interests with shareholder value creation.

Related Party Transactions

• Grant of 33,150 stock options to Carrie Brownstein, a Director of Shattuck Labs, Inc., with an exercise price of $0.82 per share, as part of her compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: While specific to a director, such grants are part of a broader compensation philosophy that can influence employee retention and motivation.

Next Steps

• Vesting of the 33,150 stock options on the earlier of July 14, 2026, or immediately prior to the Issuer's next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Shattuck Labs, STTK, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Insider Transaction, Biotechnology, Pharmaceuticals